Marinomed Biotech AG (WBO:MARI) Notes Receivable: €0.00 Mil (As of Dec. 2025)


WBO:MARI Marinomed Biotech AG WBO:MARI
42 GF Score
Price €9.45
GF Value €18.63
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Notes Receivable?

Marinomed Biotech AG WBO:MARI -1.56% 42 Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates WBO:MARI with a GF Score™ of 42/100 and a GF Value™ of €18.63 (Possible Value Trap). The stock has 7 warning signs investors should review.

Marinomed Biotech AG's Notes Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Marinomed Biotech AG Notes Receivable Related Terms

Marinomed Biotech AG Notes Receivable Historical Data

* Premium members only.

The historical data trend for Marinomed Biotech AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinomed Biotech AG Notes Receivable Chart

Marinomed Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Marinomed Biotech AG Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:MARI
42GF Score
Marinomed Biotech AG WBO:MARI
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marinomed Biotech AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Marinomed Biotech AG (WBO:MARI) has a Notes Receivable of €0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Marinomed Biotech AG and its competitors.
Is Marinomed Biotech AG's Notes Receivable too high?
Marinomed Biotech AG's current Notes Receivable is €0.00 Mil. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Notes Receivable compare to VRTX and REGN?
Marinomed Biotech AG's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.63, compared to a current price of €9.45 — trading 49.3% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €9.45 is trading 49.3% below its estimated GF Value™ of €18.63. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for WBO:MARI:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €18.63 vs. price of €9.45 (49.3% below fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marinomed Biotech AG Business Description

Other Exchanges 93Z:Germany
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score

Get the complete analysis for WBO:MARI

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.45
Price
€18.63
GF Value